Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01913639
First received: July 29, 2013
Last updated: June 27, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)